Erythroleukemia
Template:DiseaseDisorder infobox
|
WikiDoc Resources for Erythroleukemia |
|
Articles |
|---|
|
Most recent articles on Erythroleukemia Most cited articles on Erythroleukemia |
|
Media |
|
Powerpoint slides on Erythroleukemia |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Erythroleukemia at Clinical Trials.gov Trial results on Erythroleukemia Clinical Trials on Erythroleukemia at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Erythroleukemia NICE Guidance on Erythroleukemia
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Erythroleukemia Discussion groups on Erythroleukemia Patient Handouts on Erythroleukemia Directions to Hospitals Treating Erythroleukemia Risk calculators and risk factors for Erythroleukemia
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Erythroleukemia |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Erythroleukemia (or "acute Di Guglielmo syndrome") is a rare form of acute myeloid leukemia where the myeloproliferation is of erythrocyte precursors.
It is defined at type "M6" under the FAB classification.[1]
Types
It can be classified as follows:
- M6a; Erythroid/Myeloid
- M6b; Pure Erythroid Malignancy
Criteria for diagnosis of M6
M6a
50% or more of all nucleated bone marrow cells are erythroblasts, Dyserythropoiesis is prominent and 30% or more of the remaining cells (non- erythroid) are myeloblasts.
M6b ( Pure Erythroid Malignancy )
In rare cases the erythroid lineage is the only obvious components of an acute leukemia; a myeloblast component is not apparent. The erythroid component consists predominantly or exclusively of proerythroblasts and early basophilic erythroblasts. These cells may constitute 90% or more of the marrow elements. Despite this lack of myeloblast, these cases should be considered acute leukemias. In WHO proposal the blastic leukeimas that are limited to the erythroid series are designated pure erythroid malignancy.
Related chapters
Resources
References
Kowal-Vern A, Mazzella FM, Cotelingam JD, Shrit MA, Rector JT, Schumacher HR (2000). "Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases". Am. J. Hematol. 65 (1): 5–13. PMID 10936857.